<DOC>
	<DOCNO>NCT02281474</DOCNO>
	<brief_summary>This pilot study test Nilotinib 's ability alter abnormal protein build Parkinson disease Diffuse Lewey Body Disease patient . Patients receive Nilotinib different dos 6 month . Patients test see change three area : 1 ) disease symptom change . 2 ) level specific misfolded protein change fluid around brain spine . 3 ) Have inflammatory marker change patient 's blood fluid around brain spine . If successful , drug could use slow stop progression disorder involve abnormal collection misfolded protein . However , main purpose pilot study check safety use medication level .</brief_summary>
	<brief_title>Nilotinib Cognitively Impaired Parkinson Disease Patients 001</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<criteria>1 . Patients age 40 90 Idiopathic Parkinson 's Disease ( Significant Sinemet response ) stable medication drug regimen Ldopa and/or Dopamine agonist ( least 1 month enrollment new medication change ) moderate severe cognitive impairment ( MOCA ≤24 ) . Inclusions criterion : 1 . Written inform consent 2 . Capability willingness comply study relate criterion 3 . Patients age 4090 4 . Diagnosis PD accord UK Brain Bank Diagnostic Criteria 5 . Early PD subject MMSE 2330 . 6 . Hoehn Yahr stage &lt; 2 7 . Stable treatment ( &gt; 4 week ) MAOB inhibitor ( Selegeline 10mg/d rasagiline 1 mg/d ) allowable 8 . Patients need dopamine agonist levodopa therapy presently least next 6 month 9 . Idiopathic PD NO genetic mutation ( autosomal recessive dominant ) 10 . Detectable level CSF blood CSF AlphaSynuclein 1 . Patients know genetic form PD involve alphasynuclein . 2 . Unwillingness undergo lumbar puncture 3 . Immeasurable CSF αsynuclein . 4 . Presence dementia severe cognitive impairment would permit patient give adequate feedback potential side effect . 5 . Unwilling state UPDRS assessment . 6 . Premenopausal woman 7 . Patients autosomal recessive ( PARKIN , PINK1 DJ1 ) dominant mutation ( LRRK2 ) 8 . Patients hypokalemia , hypomagnesaemia , long QT syndrome . 9 . Concomitant drug know prolong QT interval 10 . Strong CYP3A4 inhibitor 11 . Any drug food may interact Nilotinib stated Package Insert ( PI ) . 12 . Medical history liver pancreatic disease . 13 . Clinical sign indicate syndrome idiopathic PD , include supranucelar gaze palsy , sign frontal dementia , history stroke , head injury encephalitis , cerebellar sings , early severe autonomic involvement , Babinski 's sign . 14 . History cardiovascular disease , include hypertension , myocardial infraction cardiac failure , angina , arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>